Newsroom | 49979 results

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region. Under the agreement, Biopharma and Cigalah Healthcare will support the commercialization and distribution...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Ann...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval by the US Food and Drug Administration (FDA) was based on positive results from the AMPLIFY Phase III trial, which were presented at the American Society of Hematology 2024 Annual Meeting and...

BOSTON--(BUSINESS WIRE)--Seaport presents new meta-analysis examining the impact of clinical trial design factors on placebo response in generalized anxiety disorder trials...

上海--(BUSINESS WIRE)--（ビジネスワイヤ） -- 生体内ゲノム編集療法を開発している臨床後期段階のバイオテクノロジー企業であるヨルテック・セラピューティクスは、α1-アンチトリプシン欠乏症（AATD）の治療を目的とする同社の開発中生体内塩基編集療法YOLT-202について、医師主導治験（IIT）における中間データが良好であることを発表しました。35mgおよび45mgの用量レベルで投与された評価対象患者において、安全性および忍容性が良好であることに加え、AAT値の意義のある上昇が示されました。 「今回の中間結果は、ヨルテックにとっても、重症AATDとともに生きる患者にとっても、重要かつ意義深いマイルストーンとなるものです。本治験で観察された機能的AAT値の迅速かつ力強い、そして用量依存的な上昇は、特にPiZZ遺伝子型を持つ患者において顕著であり、生体内塩基編集が単回投与による治療アプローチとして持つ変革的な可能性を裏付けています」と、ヨルテック・セラピューティクスの創設者兼最高経営責任者（CEO）であるYuxuan Wu医師は述べています。「これまでに確認されている良...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) plus acalabrutinib for the treatment of previously untreated adults with chronic lymphocytic leukemia (CLL), based on results from the Phase III AMPLIFY study. “Today’s approval represents an important step forward for people newly diagnosed with chronic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer follow...

DUBLIN--(BUSINESS WIRE)--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights...